In July 2025, CSL Behring conducted a study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

BD (Becton, Dickinson and Company) announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics.

Lonapegsomatropin is a pegylated prodrug of the human growth hormone, somatropin, administered as a subcutaneous injection once-weekly.

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome Poster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time & Welcome Reception Poster Topic: ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food ...

One global clinical trial testing astegolimab for moderate to severe COPD hit its main goal, but another did not, Genentech ...

The global Allergy Immunotherapy Market is projected for substantial growth, from an estimated USD 3.7 billion in 2025 to USD ...

Dramatic weight loss can sometimes come with dramatic side effects.